Sugi Predict

Sugi Predict / Compounds / SCHEMBL17064366

SCHEMBL17064366

SCHEMBL17064366

NC(=O)c1cccc(C(O)c2cc3ccccc3c3ccccc23)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 7/20 0.42
▸ ALDH1A1 P00352 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ CTSL P07711 1/20 0.39
▸ CHEK2 O96017 4/20 0.37
▸ POLB P06746 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ BLM P54132 1/20 0.37
▸ PMP22 Q01453 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ PKM P14618 1/20 0.36
▸ RAD52 P43351 1/20 0.36
▸ TAAR1 Q96RJ0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28547854 0.86 ALDH1A1 (0.50) PARP1ALDH1A1CTSLCHEK2SIRT2
SCHEMBL17064367 0.81 POLB (0.40) ALDH1A1KDM4EPOLBMAPTCYP3A4
SCHEMBL31067673 0.81 POLB (0.40) ALDH1A1KDM4EPOLBMAPTCYP3A4
SCHEMBL14124778 0.78 ADORA2A (0.51) ALDH1A1KDM4EPOLBMAPTCYP2C19
SCHEMBL17064635 0.77 CTSL (0.54) PARP1ALDH1A1KDM4ECTSLCHEK2
SCHEMBL17064839 0.77 CHEK2 (0.56) PARP1CTSLCHEK2POLBMAPT
SCHEMBL18604906 0.76 PARP1 (0.44) PARP1CHEK2MAPT
SCHEMBL17064517 0.76 LMNA (0.39) PARP1GAACTSLPOLBMAPT
SCHEMBL17064476 0.75 PARP1 (0.49) PARP1GAACTSLCHEK2POLB
SCHEMBL17064860 0.75 KLKB1 (0.49) PARP1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113307772-B Human plasma kallikrein inhibitors 拜奥克里斯特制药公司 2024-06-28 — — CN disclosed
US-20240150295-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-05-09 — — US disclosed
US-20240150296-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-05-09 — — US disclosed
US-11708332-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-07-25 — — US disclosed
US-11708333-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-07-25 — — US disclosed
US-11685721-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-06-27 — — US disclosed
EP-4180424-A1 SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BioCryst Pharmaceuticals, Inc. (US) 2023-05-17 — — EP disclosed
US-20230100082-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-03-30 — — US disclosed
US-20230094305-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-03-30 — — US disclosed
US-20230056538-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-02-23 — — US disclosed
US-10689346-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2020-06-23 — — US disclosed
US-10633345-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2020-04-28 — — US disclosed
US-20190322626-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2019-10-24 — — US disclosed
US-10329260-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2019-06-25 — — US disclosed
US-20180354906-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2018-12-13 — — US disclosed
US-10125102-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2018-11-13 — — US disclosed
US-20180258049-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2018-09-13 — — US disclosed
US-20170073314-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-03-16 — — US disclosed
EP-3113772-A1 HUMAN PLASMA KALLIKREIN INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2017-01-11 — — EP disclosed
WO-2015134998-A1 HUMAN PLASMA KALLIKREIN INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2015-09-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230100082-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 PARP1 1785/4885ALDH1A1 1220/4885KDM4E 1055/4885
US-20180354906-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 PARP1 1940/4885ALDH1A1 1065/4885KDM4E 1757/4885
US-20240150296-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 PARP1 1728/4885ALDH1A1 1136/4885KDM4E 954/4885
US-11708332-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 PARP1 1785/4885ALDH1A1 1220/4885KDM4E 1055/4885
US-10329260-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 PARP1 1940/4885ALDH1A1 1065/4885KDM4E 1757/4885
US-10125102-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 PARP1 1940/4885ALDH1A1 1065/4885KDM4E 1757/4885
US-20170073314-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 PARP1 1940/4885ALDH1A1 1065/4885KDM4E 1757/4885
US-20190322626-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 PARP1 1940/4885ALDH1A1 1065/4885KDM4E 1757/4885
US-20230094305-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 PARP1 1888/4885ALDH1A1 1425/4885KDM4E 1688/4885
US-20230056538-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 PARP1 1728/4885ALDH1A1 1136/4885KDM4E 954/4885
US-10633345-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 PARP1 1940/4885ALDH1A1 1065/4885KDM4E 1757/4885
US-20240150295-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 PARP1 1728/4885ALDH1A1 1136/4885KDM4E 954/4885
US-11708333-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 PARP1 1888/4885ALDH1A1 1425/4885KDM4E 1688/4885
US-20180258049-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 PARP1 1940/4885ALDH1A1 1065/4885KDM4E 1757/4885
US-11685721-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 PARP1 1728/4885ALDH1A1 1136/4885KDM4E 954/4885
US-10689346-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 PARP1 1940/4885ALDH1A1 1065/4885KDM4E 1757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.